Fig. 6: TCS2210 induces apoptosis of EOC cells.

A Hexosaminidase viability assay in A1847, A2780, OVCAR3, and OVCAR8 EOC cell lines. Data are represented as means from three independent experiments ± SEM. B Representative images of CF in A18437 and OVCAR8 cells treated with TCS2210. C Quantification of CF number and size from (B). D Left: representative image of scatterplot for Annexin V/PI apoptosis assay in A1847 and OVCAR8 cells treated with TCS2210. Right: quantification of the percentage of apoptotic cells following treatment with TCS2210. Data are represented as mean from three independent experiments ± SEM. E Representative images of A1847 and OVCAR8 spheroid formation following treatment with TCS2210. F Quantification of spheroid formation from (E). Data are represented as mean from three independent experiments ± SEM. G Western blot of A1847 and OVCAR8 cells treated with TCS2210 for 24 h and 48 h. Immunoblots were performed for IRAK1, pSTAT3, STAT3, and MYC. GAPDH served as internal control. H Left, heatmap of % viability for A1847 cells treated with various concentrations of TCS2210 and cisplatin. Right, synergy plot generated using SynergyFinder2.0 of A1847 cells treated in combination with TCS2210 and cisplatin. Data are represented as the mean from three independent experiments. I Top, the experimental design of xenotransplant study. Bottom, quantification of tumor volume of micro-dissected tumors from mice (n = 10 per group) injected IP with A2780 EOC cells and treated with either cisplatin (Cis), TCS2210 (TCS), or combination. Data represented as mean ± SEM showing all data points.